Found: 47
Select item for more details and to access through your institution.
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 7, p. 1, doi. 10.1007/s00520-023-07870-9
- By:
- Publication type:
- Article
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-30081-5
- By:
- Publication type:
- Article
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22582-6
- By:
- Publication type:
- Article
Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.
- Published in:
- Current Oncology, 2021, v. 28, n. 1, p. 661, doi. 10.3390/curroncol28010064
- By:
- Publication type:
- Article
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1365, doi. 10.1007/s40265-023-01934-0
- By:
- Publication type:
- Article
Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.
- Published in:
- Obstetrics & Gynecology International, 2018, p. 1, doi. 10.1155/2018/1867238
- By:
- Publication type:
- Article
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
- Published in:
- Cancers, 2023, v. 15, n. 12, p. 3220, doi. 10.3390/cancers15123220
- By:
- Publication type:
- Article
Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3296, doi. 10.3390/cancers12113296
- By:
- Publication type:
- Article
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1607, doi. 10.3390/cancers12061607
- By:
- Publication type:
- Article
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 416, doi. 10.3390/cancers11030416
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2005, v. 23, n. 5, p. 455, doi. 10.1007/s10637-005-2905-1
- By:
- Publication type:
- Article
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 20, p. 7162, doi. 10.1002/cam4.4260
- By:
- Publication type:
- Article
Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 9, p. 3015, doi. 10.1002/cam4.2940
- By:
- Publication type:
- Article
Additional germline findings from a tumor profiling program.
- Published in:
- BMC Medical Genomics, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s12920-018-0383-5
- By:
- Publication type:
- Article
Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancerSee related article on pages 645–9, this issue.: A Systematic Review With Metaanalyses.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 4, p. 692
- By:
- Publication type:
- Article
Optimizing clinical research procedures in public health emergencies.
- Published in:
- Medicinal Research Reviews, 2021, v. 41, n. 2, p. 725, doi. 10.1002/med.21749
- By:
- Publication type:
- Article
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.
- Published in:
- Frontiers in Oncology, 2016, p. 1, doi. 10.3389/fonc.2016.00119
- By:
- Publication type:
- Article
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
- Published in:
- Nature Communications, 2017, v. 8, n. 5, p. 15086, doi. 10.1038/ncomms15086
- By:
- Publication type:
- Article
Outcome according to residual disease (surgeon's report vs pre‐chemotherapy imaging) in patients with bevacizumab‐treated ovarian cancer: Analysis of the ROSiA study.
- Published in:
- Journal of Surgical Oncology, 2019, v. 120, n. 4, p. 786, doi. 10.1002/jso.25647
- By:
- Publication type:
- Article
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 56, n. 2, p. 154, doi. 10.1007/s00280-004-0942-7
- By:
- Publication type:
- Article
High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone.
- Published in:
- International Journal of Cancer, 2014, v. 135, n. 7, p. 1692, doi. 10.1002/ijc.28403
- By:
- Publication type:
- Article
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 2, p. 255, doi. 10.1038/s41416-022-02022-y
- By:
- Publication type:
- Article
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 3, p. 200, doi. 10.3390/cells8030200
- By:
- Publication type:
- Article
Ovarian cancer treatment: The end of empiricism?
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 18, p. 3203, doi. 10.1002/cncr.29481
- By:
- Publication type:
- Article
Discrepancies in drug approvals: A global dilemma.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 18, p. 3360, doi. 10.1002/cncr.29484
- By:
- Publication type:
- Article
Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 11, p. 1737, doi. 10.1002/cncr.29082
- By:
- Publication type:
- Article
Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 3, p. 413, doi. 10.1002/cncr.29030
- By:
- Publication type:
- Article
Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 24, p. 3932, doi. 10.1002/cncr.28933
- By:
- Publication type:
- Article
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 4, p. 603, doi. 10.1002/cncr.28414
- By:
- Publication type:
- Article
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 12, p. e2254, doi. 10.1002/onco.13971
- By:
- Publication type:
- Article
A Systematic Review of Health‐Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.
- Published in:
- Oncologist, 2018, v. 23, n. 2, p. 203, doi. 10.1634/theoncologist.2017-0297
- By:
- Publication type:
- Article
Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study.
- Published in:
- Oncologist, 2013, v. 18, n. 11, p. 1221, doi. 10.1634/theoncologist.2013-0175
- By:
- Publication type:
- Article
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium.
- Published in:
- Oncologist, 2010, v. 15, n. 8, p. 810, doi. 10.1634/theoncologist.2010-0081
- By:
- Publication type:
- Article
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
- Published in:
- Clinical Medicine Insights: Oncology, 2023, p. 1, doi. 10.1177/11795549231187264
- By:
- Publication type:
- Article
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
- Published in:
- Clinical Medicine Insights: Oncology, 2023, v. 17, p. 1, doi. 10.1177/11795549231187264
- By:
- Publication type:
- Article
Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15‐year retrospective study.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 16, p. 2782, doi. 10.1002/cncr.35331
- By:
- Publication type:
- Article
Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 17, p. 3082, doi. 10.1002/cncr.33625
- By:
- Publication type:
- Article
Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4886, doi. 10.1002/cncr.33144
- By:
- Publication type:
- Article
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Better Therapeutic Trials in Ovarian Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 4, p. 1, doi. 10.1093/jnci/dju029
- By:
- Publication type:
- Article
Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
- Published in:
- Genome Medicine, 2016, v. 8, p. 1, doi. 10.1186/s13073-016-0364-2
- By:
- Publication type:
- Article
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
- Published in:
- Current Oncology, 2022, v. 29, n. 6, p. 4354, doi. 10.3390/curroncol29060348
- By:
- Publication type:
- Article
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.
- Published in:
- BMC Cancer, 2006, v. 6, p. 263, doi. 10.1186/1471-2407-6-263
- By:
- Publication type:
- Article
Updates on systemic therapy for cervical cancer.
- Published in:
- Indian Journal of Medical Research, 2021, v. 154, n. 2, p. 293, doi. 10.4103/ijmr.IJMR_4454_20
- By:
- Publication type:
- Article